학술논문
P2.10-01 ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance.
Document Type
Article
Author
Source
Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS351-S352, 2p
Subject
Language
ISSN
15560864